Rima Patel

Breast Medical Oncologist @MountSinaiNYC @TischCancer

[ECOG-ACRIN Cancer Research Group @eaonc]

.@eaonc is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.

📅Feb 4 | 4 PM ET
🎙 @jsparano, @KalinskyKevin, @RimapatelMD
🔗https://t.co/tRepTjth6n

[ECOG-ACRIN Cancer Research Group @eaonc]

Trial Activation: EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. For more information: https://t.co/IrRNFtQ6GS cc: @KalinskyKevin, @RimapatelMD

[The ASCO Post @ASCOPost]

Adding everolimus to carboplatin in advanced #TNBC reduced the risk of disease progression or death by 52% vs carboplatin alone

By Amy Tiersten, MD, @RimapatelMD @IcahnMountSinai

https://t.co/hQqlbQ3DHx

#BCSM

#HCC #Immunotherapy

[Roberto Leon-Ferre @rleonferre]

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current

https://t.co/N0fMyRWjP3

[Rima Patel @RimapatelMD]

@NickRohsMD Excited to work together!

[Rima Patel @RimapatelMD]

Excited to be staying at Mount Sinai as an Assistant Professor in Breast Medical Oncology! Thankful for the support of my incredible mentors, family, and friends. Looking forward to this next chapter!

[Mount Sinai Tisch Cancer Center @TischCancer]

.@RimapatelMD has joined our Hem/Onc faculty. Welcome!
https://t.co/LNHDZgaD50
https://t.co/2BIZ5FHDMV
@IcahnMountSinai @DOMSinaiNYC

[Uroosa Ibrahim @uroosaibrahim]

Huge congratulations to @IcahnMountSinai @SinaiHemeOnc graduating fellows #2023 👏🎓🌟 Good luck on starting stellar careers!!

[Rima Patel @RimapatelMD]

@uroosaibrahim @IcahnMountSinai @SinaiHemeOnc @sridevirajeeve @TischCancer @tarekmd91 @angelal72927017 @lwumd323 @andrewsris1 @DOMSinaiNYC Thank you!!

[Rima Patel @RimapatelMD]

@NickRohsMD @TischCancer Thank you!!

[Matteo Lambertini, MD PhD @matteolambe]

Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm

https://t.co/lGLX61heDV

[Rima Patel @RimapatelMD]

Thank you @OncLive for the opportunity to share our findings on the relationship between race, Ki67, and Oncotype as well as palliative care use in elderly patients with breast cancer.

[OncLive.com @OncLive]

Thank you, @RimapatelMD, of @MountSinaiNYC, for stopping by at #SABCS to talk about racial disparities and elderly palliative care in breast cancer! Check out our site for the latest insights from @SABCSSanAntonio! #bcsm
https://t.co/6rMbg5E5QH

[Fauzia Riaz, MD, MHS @FauziaRiaz]

#VailWorkshop reunion at #SABCS2022 —great fun catching up friends/colleagues (missing a few in the 📸!) @AACR @ASCO @SABCSSanAntonio

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

Our expert, @RimapatelMD will give poster presentations on her latest #BreastCancer research at #SABCS22. Be sure to visit her to learn more. Find out more about @SABCSSanAntonio: https://t.co/4OtZvAg3QC

@TischCancer

[Mount Sinai Hematology/Oncology Fellowship @SinaiHemeOnc]

End-of-summer fellows & faculty picnic in Central Park replete with food, games, sun and camaraderie!
👏🏼 to our wellness committee - @AzziJacques @RimapatelMD
@sridevirajeeve @BaileyFitz @orrinpail @RSJSheppard @XuejunWang @TischCancer @IcahnMountSinai

[Matteo Lambertini, MD PhD @matteolambe]

Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain)
@OncoAlert @myESMO

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @GileadSciences announced statistically significant OS from Phase 3 TROPiCS-02: SG antibody-drug conjugate prolongs OS in heavily-pretreated patients with HR+/HER2- metastatic breast cancer

@DFCI_BreastOnc @OncoAlert, via @BusinessWire

https://t.co/TLw8hBcr8p

[Rima Patel @RimapatelMD]

Excited to share our work on the correlation between Oncotype and Ki67 using the IKWG categories. Important to consider when using Ki67 in clinical practice, especially to guide adjuvant abemaciclib @jsparano @MelanieKierMD @BZimmermanMD @TischCancer

[ACS Journal Cancer @JournalCancer]

The results of this study show no agreement between IHC-measured Ki67 using the International Ki67 Working Group prognostic groups & Oncotype DX Recurrence Score in patients with early #BreastCancer. https://t.co/LLFKDp9QNU @TischCancer @RimapatelMD @jsparano @OncoAlert

[Rima Patel @RimapatelMD]

Wrapping up an incredible week of clinical trial development at @AACR @ASCO #MCCR. Grateful to be have met and worked with these amazing oncologists! @quirogad @rleonferre @gandhi_shipra @FauziaRiaz @JingJiMD @JMcGuinnessMD @tarekmd91 @sridevirajeeve @lwumd323

[Sridevi Rajeeve, MD @sridevirajeeve]

Representing @IcahnMountSinai @TischCancer @SinaiHemeOnc at the @AACR @ASCO #MCCR22 "Vail" workshop. What a phenomenal week learning to write robust clinical trials! 📝
📸: Vail faculty @KarynAGoodman; Attendees Jr faculty Jon Feld, cofellows @RimapatelMD, @lwumd323, @tarekmd91

[Rima Patel @RimapatelMD]

Enjoying our last day in #Vail for the @AACR @ASCO #MCCR workshop with these amazing women oncologists! @sridevirajeeve @KrithikaShanm @PrincessMark17